A ‘Game Changer’ for Patients With Esophageal Cancer
WEBMar 31, 2021 · Now a large clinical trial offers hope, finding that a drug that unleashes the immune system to attack cancer cells can double the disease-free survival times in patients from 11 months to 22 ...
Clinical Trial for Esophageal Cancer Moves Treatment Forward for ...
WEBSep 12, 2024 · Designed by CU Cancer Center member Jeffrey Olsen, MD, the trial evaluates the potential of treating esophageal cancer patients with three additional rounds of a chemotherapy known as FLOT — a combination of four drugs — prior to the standard chemotherapy and radiation regimen (known together as chemoradiation) typically given prior to surgery.
How AI can help researchers make esophageal cancer less deadly
WEBSep 18, 2024 · About 22,370 times a year in the United States, those mistakes culminate in cancer. Esophageal cancer can be cured if it's discovered and treated before it burrows in deep or spreads to...
Immunotherapy Improves Survival in Advanced Esophageal Cancer
WEBJun 17, 2021 · In people with advanced esophageal cancer, combining nivolumab (Opdivo) with either chemotherapy or ipilimumab (Yervoy) improved how long they lived, according to results from a large clinical trial. Results from the trial, CheckMate 648, should change current clinical practice, experts said.
New Gastric & Esophageal Cancer Treatment Breakthrough
WEBMar 23, 2022 · There are new, FDA-authorized treatment options for people facing esophageal and gastric (stomach) cancer, thanks to clinical trials at Memorial Sloan Kettering that combined immunotherapy with standard treatments.
FDA ODAC Votes Against Checkpoint Inhibitors in PD–L1-Negative ...
WEB1 day ago · The FDA’s Oncologic Drug Advisory Committee voted against the use of checkpoint inhibitors in esophageal cancer with PD-L1 expression less than 1. 3D rendered medically accurate illustration of esophagus cancer: © Sebastian Kaulitzki - stock.adobe.com
FLOT Improves Survival in Locally Advanced Esophageal Cancer
WEBJul 9, 2024 · In the new trial, dubbed ESOPEC and funded by the German Research Foundation, 438 people with locally advanced esophageal cancer were randomly assigned to receive either perioperative chemotherapy with the FLOT regimen or neoadjuvant chemoradiation with the CROSS regimen.
New Immunotherapy Combinations for Patients with Esophageal …
WEBResults from a new phase III study found that combining PD-L1and TIGIT inhibitors plus chemotherapy in the first-line setting prolongs survival in an Asian population of patients with metastatic or locally advanced esophageal squamous cell carcinoma.
A New Immunotherapy for Esophageal Cancer | AACR
WEBMar 14, 2024 · The FDA rendered its decision on March 14, 2024. Tislelizumab-jsgr (Tevimbra) was approved to treat certain patients with unresectable or metastatic esophageal squamous cell carcinoma.
Esophageal cancer is one of the deadliest cancers
WEBMar 31, 2022 · By Dana Sparks. The sixth most common cause of cancer deaths world-wide, esophageal cancer occurs in the esophagus — a long, hollow tube that runs from the throat to the stomach — and can occur anywhere along the esophagus. Men are more likely to develop esophageal cancer than women. While treatable, esophageal cancer is …
Skip to content